C4 Therapeutics (CCCC) vs Eupraxia Pharmaceuticals (EPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Eupraxia Pharmaceuticals (EPRX) over the past year, gaining 31.1% versus a gain of 20.5%. Eupraxia Pharmaceuticals is the larger company by market cap ($492.9 million vs $388.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | EPRX |
|---|---|---|
| Share price | $3.16 | $7.46 |
| Market cap | $388.76M | $492.91M |
| 1-day change | +10.88% | -1.45% |
| YTD return | +65.45% | -1.19% |
| 1-year return | +31.12% | +20.52% |
| 5-year return | -92.80% | — |
| EPS (TTM) | $-1.01 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $9.32 |
| 52-week low | $1.69 | $5.25 |
| Distance from 52-week high | -38.88% | -19.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +306.96% | +119.17% |
| Average volume | 2.38M | 580.33K |
| Shares outstanding | 123.03M | 66.07M |
| Employees | 104 | 49 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed EPRX by 10.6 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Healthcare · Biotechnology · 49 employees
CCCC vs EPRX FAQ
Which is bigger, C4 Therapeutics or Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals (EPRX) is larger, with a market capitalization of $492.91M compared with $388.76M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, CCCC or EPRX?
CCCC returned +31.12% over the past 12 months, compared with +20.52% for EPRX (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Eupraxia Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.